Literature DB >> 14992659

An application of item response theory analysis to alcohol, cannabis, and cocaine criteria in DSM-IV.

James W Langenbucher1, Erich Labouvie, Christopher S Martin, Pilar M Sanjuan, Lawrence Bavly, Levent Kirisci, Tammy Chung.   

Abstract

Item response theory (IRT) is supplanting classical test theory as the basis for measures development. This study demonstrated the utility of IRT for evaluating DSM-IV diagnostic criteria. Data on alcohol, cannabis, and cocaine symptoms from 372 adult clinical participants interviewed with the Composite International Diagnostic Interview--Expanded Substance Abuse Module (CIDI-SAM) were analyzed with Mplus (B. Muthen & L. Muthen, 1998) and MULTILOG (D. Thissen, 1991) software. Tolerance and legal problems criteria were dropped because of poor fit with a unidimensional model. Item response curves, test information curves, and testing of variously constrained models suggested that DSM-IV criteria in the CIDI-SAM discriminate between only impaired and less impaired cases and may not be useful to scale case severity. IRT can be used to study the construct validity of DSM-IV diagnoses and to identify diagnostic criteria with poor performance.

Entities:  

Mesh:

Year:  2004        PMID: 14992659     DOI: 10.1037/0021-843X.113.1.72

Source DB:  PubMed          Journal:  J Abnorm Psychol        ISSN: 0021-843X


  105 in total

1.  Modeling the impact of age and sex on a dimension of poly-substance use in adolescence: a longitudinal study from 11- to 17-years-old.

Authors:  Jaime Derringer; Robert F Krueger; William G Iacono; Matt McGue
Journal:  Drug Alcohol Depend       Date:  2010-04-24       Impact factor: 4.492

2.  Alcohol craving and the dimensionality of alcohol disorders.

Authors:  K M Keyes; R F Krueger; B F Grant; D S Hasin
Journal:  Psychol Med       Date:  2010-05-12       Impact factor: 7.723

3.  Abuse and dependence on prescription opioids in adults: a mixture categorical and dimensional approach to diagnostic classification.

Authors:  L-T Wu; G E Woody; C Yang; J-J Pan; D G Blazer
Journal:  Psychol Med       Date:  2010-05-12       Impact factor: 7.723

4.  Marijuana use subtypes in a community sample of young adult women.

Authors:  Marcel A de Dios; Bradley J Anderson; Debra S Herman; Claire E Hagerty; Celeste M Caviness; Alan J Budney; Michael Stein
Journal:  Womens Health Issues       Date:  2010 May-Jun

5.  DSM-IV to DSM-5: the impact of proposed revisions on diagnosis of alcohol use disorders.

Authors:  Arpana Agrawal; Andrew C Heath; Michael T Lynskey
Journal:  Addiction       Date:  2011-08-18       Impact factor: 6.526

6.  The dimensionality of alcohol use disorders: results from Israel.

Authors:  Dvora Shmulewitz; Katherine Keyes; Cheryl Beseler; Efrat Aharonovich; Christina Aivadyan; Baruch Spivak; Deborah Hasin
Journal:  Drug Alcohol Depend       Date:  2010-05-26       Impact factor: 4.492

7.  Relationship of substance abuse to dependence in the U.S. general population.

Authors:  Tulshi D Saha; Thomas Harford; Risë B Goldstein; Bradley T Kerridge; Deborah Hasin
Journal:  J Stud Alcohol Drugs       Date:  2012-05       Impact factor: 2.582

8.  Revising the Cannabis Use Disorders Identification Test (CUDIT) by means of Item Response Theory.

Authors:  Beatrice Annaheim; Thomas J Scotto; Gerhard Gmel
Journal:  Int J Methods Psychiatr Res       Date:  2010-09       Impact factor: 4.035

9.  Comparing factor, class, and mixture models of cannabis initiation and DSM cannabis use disorder criteria, including craving, in the Brisbane longitudinal twin study.

Authors:  Thomas S Kubarych; Kenneth S Kendler; Steven H Aggen; Ryne Estabrook; Alexis C Edwards; Shaunna L Clark; Nicholas G Martin; Ian B Hickie; Michael C Neale; Nathan A Gillespie
Journal:  Twin Res Hum Genet       Date:  2014-03-03       Impact factor: 1.587

10.  Reliability of use, abuse, and dependence of four types of inhalants in adolescents and young adults.

Authors:  Ty A Ridenour; Bethany C Bray; Linda B Cottler
Journal:  Drug Alcohol Depend       Date:  2007-06-18       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.